Ali Kürşat TUNA, Atakan TEKİNALP, İbrahim KILINÇ, Sinan DEMİRCİOĞLU, Özcan ÇENELİ
Acta Haematologica Oncologica Turcica - 2026;59(1):1-5
Aim: This study aimed to perform a descriptive evaluation of serum periostin levels in newly diagnosed, treatment-naive multiple myeloma (MM) patients and to explore short-term changes following induction therapy. Methods: Between May 2020 and May 2021, patients diagnosed with MM and healthy volunteers were recruited from the Hematology Unit of the Faculty of Medicine, Necmettin Erbakan University. Demographic characteristics, MM-related clinical findings, and treatment response data of the patients were documented. Serum periostin levels in MM patients before treatment were compared with those in healthy controls. Additionally, baseline periostin levels in the patient group were compared with post-treatment values. Results: Thirty-six MM patients were included in our study (17 females, 47.2%; 19 males, 52.8%), with an average age of 63.11+/-12.13 years. The control group consisted of 18 males (50%) and 18 females (50%), with a mean age of 61.94+/-10.53 years. Serum periostin levels were significantly elevated in the MM group compared with controls healthy (25.25 ng/mL vs. 14.84 ng/mL, p<0.001). No statistically significant associations were observed between baseline periostin levels and disease stage, cytogenetic risk groups, survival, or treatment response. In the 28 patients who completed induction chemotherapy, the median periostin value decreased from 24.96 (11.21-94.87) ng/mL at diagnosis to 17.97 (3.16-47.7) ng/mL after three courses of treatment (p<0.001). Conclusion: In MM patients, serum periostin levels were elevated at diagnosis and decreased significantly following induction therapy. This study is the first to demonstrate a significant reduction in periostin levels after induction therapy in MM. These findings should be considered preliminary and hypothesis-generating. Larger, well-designed studies are required to clarify the clinical relevance of periostin in MM.
